ES 3001
Alternative Names: ES-3001Latest Information Update: 22 May 2024
At a glance
- Originator Eicos Sciences
- Class 2 ring heterocyclic compounds; Prostaglandins; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Vascular disorders
Most Recent Events
- 30 Apr 2024 Preclinical trials in Autoimmune disorders in USA (SC), prior to April 2024 (EICOS sciences pipeline, April 2024)
- 30 Apr 2024 Preclinical trials in Vascular disorders in USA (SC), prior to April 2024 (EICOS sciences pipeline, April 2024)